Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial

Pliant Therapeutics Inc. shares (PLRX) gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic liver disease. The trial met its primary and secondary goals, and bexotegrast was well tolerated over a 12-week treatment period in patients with primary sclerosing cholangitis (PSC) and suspected liver fibrosis, the company said in a release. In PSC, which affects more than 30,000 people in the U.S. and has no treatment currently approved by the Food and Drug Administration, bile can build up in the liver and cause damage. Pliant is also looking to broaden future development of bexotegrast into other pulmonary and liver indications, the company said. Pliant shares are down 24% in the year to date, while the S&P 500 has gained 13%.

-Eleanor Laise

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

09-26-23 0809ET

Copyright (c) 2023 Dow Jones & Company, Inc.